VIKING GLOBAL INVESTORS LP 13D and 13G filings for Edgewise Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale |
2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 1,481,146 1.600% |
-4,678,000 (-75.95%) |
Filing |
| 2024-02-14 10:26 am Purchase |
2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 6,159,146 9.700% |
1,750,000 (+39.69%) |
Filing |
| 2023-02-14 1:17 pm Purchase |
2022-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 4,409,146 7.000% |
1,681,897 (+61.67%) |
Filing |
| 2022-02-14 5:02 pm Sale |
2021-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 2,727,249 5.500% |
-625,032 (-18.64%) |
Filing |
| 2021-04-05 3:20 pm Purchase |
2021-03-26 | 13G | Edgewise Therapeutics, Inc. EWTX |
VIKING GLOBAL INVESTORS LP | 3,352,281 7.000% |
3,352,281 (New Position) |
Filing |